DDD Partners’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$933K Sell
3,566
-822
-19% -$211K 0.05% 102
2026
Q2
$1.1M Sell
4,388
-87,009
-95% -$18.7M 0.07% 78
2026
Q1
$19.9M Buy
91,397
+2,757
+3% +$612K 1.37% 20
2025
Q4
$20.3M Buy
88,640
+234
+0.3% +$53.3K 1.29% 21
2025
Q3
$20.5M Sell
88,406
-18,274
-17% -$3.72M 1.3% 16
2025
Q2
$19.8M Sell
106,680
-5,843
-5% -$1.09M 2.12% 20
2025
Q1
$23.6M Sell
112,523
-12,822
-10% -$2.49M 2.86% 10
2024
Q4
$22.3M Buy
125,345
+11,168
+10% +$2.05M 2.74% 12
2024
Q3
$22.5M Buy
114,177
+507
+0.4% +$94.6K 2.45% 16
2024
Q2
$19.5M Buy
113,670
+365
+0.3% +$60.5K 2.26% 17
2024
Q1
$20.6M Sell
113,305
-19,002
-14% -$3.27M 2.52% 13
2023
Q4
$20.5M Sell
132,307
-822
-0.6% -$120K 2.76% 12
2023
Q3
$19.7M Sell
133,129
-2,544
-2% -$373K 2.85% 8
2023
Q2
$18.3M Buy
135,673
+134,327
+9,980% +$19.7M 2.53% 16
2023
Q1
$215K Buy
1,346
+5
+0.4% +$764 0.03% 75
2022
Q4
$217K Buy
+1,341
New +$206K 0.03% 73

Other funds holding ABBV

DDD Partners's ABBV Position: Q3 2026 in Review

DDD Partners reduced its AbbVie (ABBV) stake by 19% in Q3 2026, selling an estimated $211K and leaving 3,566 shares worth $933K. The position accounts for 0.05% of the portfolio, ranked #102.

DDD Partners first reported a position in ABBV in Q4 2022 and has held it in 16 quarters since. The position peaked at $23.6M in Q1 2025. 2,580 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • DDD Partners held 3,566 shares of AbbVie worth $933K as of Q3 2026.
  • DDD Partners sold 822 AbbVie shares in Q3 2026, an estimated $211K.
  • AbbVie made up 0.05% of DDD Partners's portfolio in Q3 2026, its #102 holding.
  • DDD Partners first reported a position in AbbVie in Q4 2022 and has held it in 16 quarters since.
  • DDD Partners's AbbVie position peaked at $23.6M in Q1 2025.
  • 2,580 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on DDD Partners's 13F filing for Q3 2026, filed 2 Nov 2026.